Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Net Income towards Common Stockholders: 2016-2019

Historic Net Income towards Common Stockholders for Monopar Therapeutics (MNPR) over the last 4 years, with Dec 2019 value amounting to -$4.3 million.

  • Monopar Therapeutics' Net Income towards Common Stockholders fell 32.23% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.3 million, marking a year-over-year decrease of 36.88%. This contributed to the annual value of -$4.3 million for FY2019, which is 31.04% down from last year.
  • Latest data reveals that Monopar Therapeutics reported Net Income towards Common Stockholders of -$4.3 million as of FY2019, which was down 31.04% from -$3.3 million recorded in FY2018.
  • In the past 5 years, Monopar Therapeutics' Net Income towards Common Stockholders ranged from a high of -$1.2 million in FY2016 and a low of -$16.6 million during FY2017.
  • For the 3-year period, Monopar Therapeutics' Net Income towards Common Stockholders averaged around -$8.1 million, with its median value being -$4.3 million (2019).
  • In the last 5 years, Monopar Therapeutics' Net Income towards Common Stockholders plummeted by 1,287.87% in 2017 and then skyrocketed by 80.07% in 2018.
  • Monopar Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$1.2 million in 2016, then crashed by 1,287.87% to -$16.6 million in 2017, then spiked by 80.07% to -$3.3 million in 2018, then crashed by 31.04% to -$4.3 million in 2019.